Get started
Fulcrum Therapeutics, Inc.Fulcrum Therapeutics, Inc.Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

FULC trade ideas

FULC - Pre Run-Up Biotech Catalyst PlayFulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. On October 10, 2024 there will be Phase 3 Data released - i expect a pre run up into the catalyst. Breakout Zone: $9.50 Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend. Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions. Resistance Points: $9.50 $11.30 $12.50 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: Take Profit (TP): Set a target at $14.20 maybe even 21.00 is possible if catalyst will be positive. Stop Loss (SL): Set at under $7.90 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:FULCLong
by meitshels_smell_trades
FULC fades after a big move for a SHORT tradeFULC a biotechnology firm with a mixed earnings report early in the month just printed a big move and then stalled at the NY lunch - hour and faded. Will the fade continue or will there be an upward continuation? The 15 -minute chart seems to suggest a downtrend: 1, The volume profile shows heavy trading at the top. This could be short sellers and late-coming long trades. Once a trend down is underway, the short sellers will begin to take profits buying to cover while the long trades will sell at a loss. Probably at this level there will be more longs exiting than shorts until a substantial fall dictates the latter to buy to cover. 2. New short sellers will pile into the trade pushing price down while few new long traders will participate in accelerating the move down. 3. The relative strength on that indicator falling confirms the trend as does the Average Positive Directional Index falling with the combined falling as well. 4. The mass index indicator documents a reversal Accordingly, I will take a short trade and assist the trend down in my own little way. I may take a trade of 100 shares and then sell a call option. In the meanwhile, I will take a put option striking $5.00 for September 15th. I expect a decent realized profit from these trades in this at least currently high volatility biotechnology penny stock.
NASDAQ:FULCShort
by AwesomeAvani
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price rise in the after-hours which is typically a busy trading period for biotechnology penny stocks. I will take a long trade on FULC in after hours and take off a part of the position in the next trading day and hold the rest through the weekend.
NASDAQ:FULCLong
by AwesomeAvani
$FULC is gonna fall todayPupm&Dump trading strategy idea. $FULC is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $20,49; stop-loss — $21,32; take-profit — $18,82/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:FULCShort
by KozakHlib
3
FULC SendFULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next. "The company focuses on developing treatments for rare genetic diseases. including sickle cell disease. This week, the company announced key data that has helped drive momentum in the market and push shares of FULC stock higher. Fulcrum announced positive interim results from its ongoing single- and multiple ascending dose (SAD and MAD) Phase 1 trial with FTX-6058. This treatment targets patients with fetal hemoglobin (HbF) with the potential to treat hemoglobinopathies." Quote Source & Read More: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%
NASDAQ:FULC
by PennyStocks101
FULC, Technical reversal play .First of All , shout out to Horizontal Price Levels Trading (on tradingview), I originally read their publication on FULC which was what spurred my original interest. Secondly, Bio-tech is NOT my strong point , as I do not have a medical background and reading the news reports these kinds of stocks produce can be hard for me to comprehend Example from Quoted text from a recent report: "Results from the interim analysis in the first 29 randomized subjects indicated that DUX4-driven gene expression did not separate from placebo at 16 weeks." Me: but what does it mean ? >.< If you know what it means feel free to share but my point is that I have no idea if thats bearish or bullish . So , All that out of the way now , strictly technically speaking, I think FULC has some fuel the indicators look nice and I do like that they beat on their recent earnings too (15.27% Suprise).
NASDAQ:FULCLong
by NAK1987
2
$FULC Breakout alert setup in Fulcrum Therapeutics Entry level $15.96 = Target price $20.63 Alert set for breakout above $15.61 Average analysts price target $12 | Buy rating Earnings call transcript We believe our approach to the treatment of genetically defined diseases using a small molecule approach may offer significant advantages over other treatment modalities since small molecules can achieve broad biodistribution throughout the body, have an increased likelihood of tolerability, have well-defined manufacturing and quality control requirements, and can offer ease and patient access. Fulcrum’s product engine has enabled the progress of the lead programs in our pipeline. Our most advanced candidate is losmapimod, a selective p38 alpha/beta mitogen-activated protein kinase, MAPK inhibitor. Losmapimod is being evaluated in ongoing Phase 2 trials for the treatment of FSHD. And we began enrolling in these trials in August. FSHD is a serious and progressive disease characterized by muscular degeneration in which skeletal muscle is replaced by fat. There are no currently approved treatments for FSHD and no other known industry sponsored programs in clinical development. Patients with FSHD experience significant physical impairment and disability over time, which can severely impact their day-to-day function and quality of life. The root cause of FSHD is the aberrant expression of the DUX4 gene. Using our product engine, we made the novel discovery that P38 inhibitors including losmapimod, reduce the aberrant expression of the DUX4 gene. In February of this year, we obtained the exclusive worldwide license to losmapimod from GlaxoSmithKline, which allows Fulcrum to utilize the significant safety database that GSK generated with losmapimod during their previous studies in other indications. In October, we presented Phase 1 data from the losmapimod trial in FSHD patients at the International Annual Congress of the World Muscle Society. Losmapimod was well tolerated in FSHD patients with no serious adverse events reported with doses up to 15 mg taken orally, twice daily for 14 days. Importantly, we also showed that losmapimod achieved dose dependent concentrations in muscle and that are twice daily 15 mg dose resulted in sustained and robust target inhibition in blood. These levels of drug and targeted inhibition have been shown in preclinical studies to reduce DUX4 as well as DUX4 driven gene expression and restore muscle function. The data from the Phase 1 study supports the selection of 15 mg BID of losmapimod as the appropriate dose for our ongoing Phase 2 clinical trials. ReDUX4 is a Phase 2, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of losmapimod in FSHD patients over 24 weeks. We are in the process of enrolling 66 patients randomized one-to-one in the trial with a plan to open label extension to follow. The primary endpoint of the ReDUX4 study is DUX4 activity in effected skeletal muscle at 16 weeks as measured by quantitative RT-PCR in a panel of DUX4 regulated gene transcripts. Secondary endpoints include the continued evaluation of safety and tolerability, PK and blood, losmapimod concentration in skeletal muscle biopsies and targeted engagement in blood and in skeletal muscle. This study encompasses up to 20 sites across five countries including the U.S., Canada and three countries in Europe. COMPANY PROFILE Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
NASDAQ:FULCLong
by Bullishcharts